TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04475627

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular Magnetic Resonance (CMR) imaging at 1.5T
Description: Long and short axis bSSFP cines images, long and short axis tagging images and aortic cine images will be obtained. Participants will be randomised to either have cine or tagging images obtained first.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular Magnetic Resonance (CMR) imaging at 1.5T
Description: Long and short axis bSSFP cines images, long and short axis tagging images and aortic cine images will be obtained. Participants will be randomised to either have cine or tagging images obtained first.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular Magnetic Resonance (CMR) imaging at 3T
Description: Long and short axis bSSFP cines images, long and short axis tagging images and aortic cine images will be obtained. Participants will be randomised to either have cine or tagging images obtained first.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular Magnetic Resonance (CMR) imaging at 3T
Description: Long and short axis bSSFP cines images, long and short axis tagging images and aortic cine images will be obtained. Participants will be randomised to either have cine or tagging images obtained first.
Study: NCT03295136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Promotion Training for Women Employees
Description: Group intervention over a one year, acquiring health promotion tools and skills, as well as leadership and project designing and implementation skills.
Study: NCT02447471

Intervention type: DEVICE
Intervention: Nexfin
Description: Nexfin cuff placed on finger to measure blood pressure
Study: NCT04245176

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Genetic Counseling
Description: Standard genetic counseling: Standard of care discussion

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quantitative Genetic Counseling
Description: Quantitative genetic counseling: Discussion is guided by tables and graphs.
Study: NCT02156440

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SierraSil Joint Formula 14
Description: 667 mg SierraSil® hydrothermal mineral complex

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00704951

Intervention type: DRUG
Intervention: Posaconazole or alternative fungal treatment
Description: Dosage of Posaconazole:~Prophylactic dosing: 200mg tid (600mg/day) Treatment dosing: 400mg bid (800mg/day)
Study: NCT04464408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: 1800 mg twice daily for one day, followed by 800mg (4 tablets) twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: (9 tablets) by mouth twice daily for one day, followed by (4 tablets) twice daily (Maximum days of therapy is 7 days)
Study: NCT03581370

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 hour infusion
Description: Intravenous administration of ceftolozane-tazobactam (ZERBAXA®) : 2000 mg by infusion for 60 minutes every 8 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 hours infusion
Description: Intravenous administration of ceftolozane-tazobactam (ZERBAXA®) : 2000 mg by infusion for 4 hours every 8 hours
Study: NCT01085240

Intervention type: OTHER
Group type: OTHER
Intervention: Mission Possible
Description: The intervention focuses on leisure education, exercise and community re-integration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mission Possible
Description: The intervention focuses on leisure education, exercise and community re-integration.
Study: NCT03610880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-2349 (400 mg) plus DAG181 (200 mg)
Description: Dosing period 1 (Day 1 to 7): TG-2349 400 mg； Dosing period 2 (Day 8 to 14): TG-2349 400 mg + DAG181 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAG181 (200 mg) plus TG-2349 (400 mg)
Description: Dosing period 1 (Day 1 to 7): DAG181 200 mg； Dosing period 2 (Day 8 to 14): TG-2349 400 mg + DAG181 200 mg
Study: NCT02853071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estramustine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard practice
Description: standard practice
Study: NCT03913871

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Texts to support healthy eating
Description: The intervention arm will receive tailored text messages to encourage healthy eating (increase consumption, fruits, vegetables and water; and a reduce intake of sugar sweetened beverages). Participants will receive an average of 1-2 messages per day for 4 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Texts to support physical activity
Description: The intervention arm will receive tailored text messages to support increased minutes of physical activity per day. Participants will receive an average of 1-2 messages per day for 4 weeks.
Study: NCT01234064

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Embolism Graduated Pressure Stockings (by BSN-Jobst)
Description: Apply 2 to 4 hours prior to surgery. Patient will continue to wear stockings until post-op Day 10.

Intervention type: DEVICE
Group type: OTHER
Intervention: No Graduated Compression Stockings
Description: No stockings will be applied.
Study: NCT02073539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stryker ST104-747
Description: 760 x 2110 mm, 228 kg, Stryker Co., Kalamazoo, Michigan, US

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stryker ST104-747
Description: 760 x 2110 mm, 228 kg, Stryker Co., Kalamazoo, Michigan, US

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stryker ST104-747
Description: 760 x 2110 mm, 228 kg, Stryker Co., Kalamazoo, Michigan, US

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shinchang SB-34p
Description: , 850 x 2080 mm,Shinchang Co.,Busan,ROK

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shinchang SB-34p
Description: , 850 x 2080 mm,Shinchang Co.,Busan,ROK

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shinchang SB-34p
Description: , 850 x 2080 mm,Shinchang Co.,Busan,ROK
Study: NCT00121290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SJG-136
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02263378

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ellagic acid + annona muricata
Description: pills

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ellagic acid + annona muricata
Description: pills
Study: NCT01800799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baktar 800mg h.s.
Description: Antimicrobial agent (Baktar 800mg h.s.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baktar 800mg h.s.
Description: Antimicrobial agent (Baktar 800mg h.s.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib 200mg QD
Description: Anti-inflammatory agent (Celecoxib 200mg QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib 200mg QD
Description: Anti-inflammatory agent (Celecoxib 200mg QD)
Study: NCT02254356

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zilver Flex Bare Metal Stent
Study: NCT03326297

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathy manual therapy
Description: Technique for the treatment of parasympathetic innervation, Techniques for the treatment of sympathetic innervation of the digestive system, Functional visceral techniques.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Measures to support and education to the family
Description: Pedagogical intervention in parents and health education
Study: NCT00985686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LEAP Project
Description: In collaboration with experts from Alberta Health Services, the University of Calgary, and Mount Royal University, the Canadian Institute of Natural and Integrative Medicine (CINIM) has created the LEAP Project, a spirituality informed e-mental health intervention, for young people with major depressive disorders (see Appendix for sample materials). It is an online, eight module, multimedia intervention delivered over eight weeks, requiring a weekly commitment of 2-3 hours. The intervention is non-denominational and avoids a focus on any religious traditions. The program aims to treat depression by guiding depressed young people through an exploration of spiritual concepts and principles.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LEAP Project
Description: In collaboration with experts from Alberta Health Services, the University of Calgary, and Mount Royal University, the Canadian Institute of Natural and Integrative Medicine (CINIM) has created the LEAP Project, a spirituality informed e-mental health intervention, for young people with major depressive disorders (see Appendix for sample materials). It is an online, eight module, multimedia intervention delivered over eight weeks, requiring a weekly commitment of 2-3 hours. The intervention is non-denominational and avoids a focus on any religious traditions. The program aims to treat depression by guiding depressed young people through an exploration of spiritual concepts and principles.
Study: NCT03134911

Intervention type: DRUG
Intervention: DOAC or VKA
Description: 6 months - 2 years

Intervention type: DRUG
Intervention: VKA
Description: 6 months - 2 years
Study: NCT01008813

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adjuvanted A(H1N1)v influenza vaccine
Description: Two intramuscular injections at day 0 and day 21 of FLU D-PAN H1N1 \[A/California/7/2009 (H1N1)v\] (3,8 microgram) adjuvanted with AS 03A

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: non-adjuvanted A(H1N1)v influenza vaccine
Description: Two intramuscular injections at day 0 and day 21 of FLU D-PAN H1N1 \[A/California/7/2009 (H1N1)v\] (15 microgram)
Study: NCT01468571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: 50 mg po daily of spironolactone for 8 weeks. A cross-over study where each subject will receive spironolactone or placebo in a random order for 8 weeks each.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Each subject will receive placebo or spironolactone for 8 weeks. At the end of week 8, treatment arm for each subject will be blindly switched.~So if a study patient received placebo for the first 8 weeks then he/she will be switched to receive active drug (spironolactone) for the next 8 weeks.
Study: NCT02780271

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-person education
Description: Four in-person hands-on nutrition and physical activity education classes and cooking sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-person education
Description: Four in-person hands-on nutrition and physical activity education classes and cooking sessions.
Study: NCT01055847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aztreonam for Inhalation (AI)
Description: Aztreonam for Inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aztreonam for Inhalation (AI)
Description: Aztreonam for Inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline Placebo
Study: NCT02534571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic Application of a Hemostatic Powder TC-325
Description: Endoscopic Application of a Hemostatic Powder TC-325 \<=150g once

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemo-clipping
Description: Hemo-clipping \<=20 clips

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: epinephrine injection endoscopically \<20 mls

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: thermo-coagulation
Description: contact thermo-coagulation \< = 4 pulses
Study: NCT03197753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Description: Laryngeal mask airway

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasotracheal intubation
Description: Nasotracheal intubation
Study: NCT00569023

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: alga Dunaliella bardawil
Description: Each patients will be treated with four capsules daily of Dunaliella bardawil for 90 days.~Alga Dunaliella bardawil containing 15 mg approximately 50% all-trans beta-carotene and 50% 9-cis beta-carotene isomers
Study: NCT01055704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone only
Description: 0.30 mg/kg subcutaneous injection daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Codeine only
Description: 30 mg taken orally four times daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone + codeine
Description: Methylnaltrexone 0.30 mg/kg by subcutaneous injection once daily and codeine 30 mg taken orally four times daily for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + placebo
Description: Placebo subcutaneous injection once daily and placebo taken orally four times daily for 5 days
Study: NCT01971151

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure therapy
Description: Treatment protocol:~1) preparation consisting of intake and identification of feared movements, activities and situations and their underlying catastrophic beliefs. 2) education, 3)exposure sessions: patients confront threatening situations and behavioral experiments are performed that are targeted at correcting erroneous catastrophic beliefs. 4) homework assignments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure therapy
Description: Treatment protocol:~1) preparation consisting of intake and identification of feared movements, activities and situations and their underlying catastrophic beliefs. 2) education, 3)exposure sessions: patients confront threatening situations and behavioral experiments are performed that are targeted at correcting erroneous catastrophic beliefs. 4) homework assignments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure therapy
Description: Treatment protocol:~1) preparation consisting of intake and identification of feared movements, activities and situations and their underlying catastrophic beliefs. 2) education, 3)exposure sessions: patients confront threatening situations and behavioral experiments are performed that are targeted at correcting erroneous catastrophic beliefs. 4) homework assignments.
Study: NCT01038427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate 50 mcg/actuation nasal spray (Lek Pharmaceuticals)
Description: Mometasone nasal spray administered once daily at a dose of 200 mcg (4 actuations) for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone furoate (Nasonex®) 50 mcg/actuation nasal spray
Description: Mometasone nasal spray administered once daily at a dose of 200 mcg (4 actuations) for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray administered once daily (4 actuations) for 14 days.
Study: NCT03872245

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: The patients will receive Adomelle 1caps/12h during 10 weeks
Study: NCT02780271

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-communication
Description: 11 months of motivational text messages, emailed newsletters, and access to a website.
Study: NCT03872245

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PENS T6
Description: The patients will undergo percutaneous electrical neurostimulation of dermatome T6 weekle, during 10 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PENS T6
Description: The patients will undergo percutaneous electrical neurostimulation of dermatome T6 weekle, during 10 weeks
Study: NCT02825342

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Study: NCT01827046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rt-PA
Description: Up to 9 doses of 1.0 mg of rt-PA will be administered through the catheter that was placed directly into the intracerebral hemorrhage using minimally invasive surgery.
Study: NCT00770900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: Asthmatic children and teenagers took montelukast daily for 12 weeks.~Children aged 2-5 years took 4mg tablet of montelukast~Children aged 6-15 years took 5mg tablet of montelukast~Children \>15 years took 10mg tablet of montelukast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo comparator
Description: Asthmatic children and teenagers took Placebo tablet daily for 12 weeks.
Study: NCT00329680

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid, Gamma-Linolenic Acid and Antioxidant Vitamins
Description: An enteral diet will be given in accordance with the caloric goal calculated by the Harris-Benedict equation x 1.3. The enteral diet will be provided for a period of 7 days or until death OR start of oral diet OR start of parenteral diet OR discharge from the ICU OR decision from the attending physician/family/patient to no longer participate in this clinical study

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Standard ICU enteral diet, isocaloric to the study diet
Description: Patients will receive this diet in a blinded way using the same dose regimen specified previously and used in the study group
Study: NCT01670253

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 1
Description: * 6 hour fast from all solid foods and milk beverages~* 2-hour thirst period before examination (patient may be in the period from 6 to 2 hours before the study drink any kind of clear liquids, ie liquids containing no milk products)~* Approximately 2 hours before the time of examination please drink a glass (about 2 cups) clear sugary liquid - eg lemonade, apple juice, iced tea, soda or the like.
Study: NCT03037203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JZP-110
Description: 75 mg, 150 mg, 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JZP-110
Description: 75 mg, 150 mg, 300 mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03985696

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blood sample
Description: 1 blood volume (5-7 ml EDTA)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample
Description: 1 blood volume (5-7 ml EDTA)
Study: NCT01922388

Intervention type: DEVICE
Intervention: Bilateral deep brain stimulation of the subthalamic nucleus

Intervention type: DEVICE
Intervention: Bilateral deep brain stimulation of the subthalamic nucleus
Study: NCT02152943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study: NCT01788293

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention group
Description: Control group will receive per-operative fluid at the discretion of the anesthetist, whereas Intervention group will receive additional hydroxyethylstarch 6% (HES) bolus in order to minimize and maintain PVI below 14 %.~This PVI cut-off value was chosen according to previous reports \[Cannesson et al., 2008; Zimmermann et al., 2010\].~During the postoperative period, both groups were managed by intensivists (in the ICU) and clinicians (in the wards) not involved in the intraoperative management or in data collection. These individuals were not informed of patient allocation.
Study: NCT01808677

Intervention type: OTHER
Intervention: Thoracic Reirradiation Registry
Description: Data collected in the registry includes patient characteristics/demographics, disease characteristics, treatment details (radiation, chemotherapy, surgery, etc.), toxicity rates, and survival outcomes.
Study: NCT03321253

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nd: YAG laser posterior capsulotomy
Description: Nd: YAG laser posterior capsulotomy
Study: NCT01275781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-AZD9742
Description: 1000 mg intravenous over 2 hours
Study: NCT01635023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244 Dosing Period 1
Description: Treatment A, B, or C depending on randomization assignment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244 Dosing Period 1
Description: Treatment A, B, or C depending on randomization assignment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244 Dosing Period 1
Description: Treatment A, B, or C depending on randomization assignment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244 Dosing Period 2
Description: Treatment A, B, or C depending on randomization assignment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244 Dosing Period 2
Description: Treatment A, B, or C depending on randomization assignment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244 Dosing Period 2
Description: Treatment A, B, or C depending on randomization assignment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244 Dosing Period 3
Description: Treatment A, B, or C depending on randomization assignment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244 Dosing Period 3
Description: Treatment A, B, or C depending on randomization assignment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244 Dosing Period 3
Description: Treatment A, B, or C depending on randomization assignment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244 Dosing Period 4
Description: Treatment B
Study: NCT01989169

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSP-004184SS
Study: NCT02071277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure targeted modes
Description: Intervention involving three different pressure-targeted modes (APRV, BIPAP, and BIPAPassist) each in a random order generated by a computer on one ventilator. Each mode will be studied for 20 minutes.